Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease ( AMBER ): results in the pre‐specified subgroup with heart failure-Reference-Cited by-同舟云学术

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease ( AMBER ): results in the pre‐specified subgroup with heart failure

Published:2020-05-25 Issue:8 Volume:22 Page:1462-1471
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Rossignol Patrick¹,Williams Bryan²,Mayo Martha R.³,Warren Suzette³,Arthur Susan³,Ackourey Gail³,White William B.⁴,Agarwal Rajiv⁵

Affiliation:

1. Université de Lorraine, Inserm 1433 CIC‐P CHRU de Nancy, Inserm U1116 and FCRIN INI‐CRCT Nancy France

2. Institute of Cardiovascular Science University College London (UCL) and National Institute for Health Research (NIHR) UCL/UCL Hospitals Biomedical Research Centre London UK

3. Relypsa, Inc., a Vifor Pharma Group Company Redwood City CA USA

4. Calhoun Cardiology Center University of Connecticut School of Medicine Farmington CT USA

5. Department of Medicine, Division of Nephrology Indiana University School of Medicine Indianapolis IN USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.1860

Reference21 articles.

1. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

2. 2018 ESC/ESH Guidelines for the management of arterial hypertension